An up­date on the End­points busi­ness mod­el — and how your com­pa­ny can di­rect­ly sup­port it

Pic­tured: The print-op­ti­mized ver­sion of End­points’ 2018 New Drug Ap­provals re­port. All paid sub­scribers will re­ceive a di­rect link to down­load the PDF + a copy of all our Q1 pay­wall sto­ries in print­able form, too.

Sign-up for En­ter­prise (com­pa­ny plan)
Sign-up for In­sid­er (in­di­vid­ual plan)


I want to give read­ers an up­date on the busi­ness front at End­points News, which is strong.

Two and a half years in — we’re prof­itable, about 14 peo­ple on the team and grow­ing, and 75,000 unique bio­phar­ma read­ers con­sume our news across all plat­forms on a week­ly ba­sis. Of that, 31,000 are what we con­sid­er “ba­sic sub­scribers” who re­ceive our dai­ly email re­ports and have opened or clicked on them in the last month, but haven’t up­grad­ed to paid sta­tus. And at the top we have 8,300 pre­mi­um sub­scribers who ei­ther di­rect­ly sup­port the work or are em­ployed at a com­pa­ny that does.

We reg­u­lar­ly scrub our email read­er­ship, too.

We’ve built a glob­al events fran­chise and con­vened over 2,000 at­ten­dees over the last 12 months in San Fran­cis­co, Boston, Lon­don, and Shang­hai. Lat­er this month we’ll be an­nounc­ing venues and dates for our en­tire 2019 line­up.

John Car­roll speaks at the US-Chi­na Bio­phar­ma In­no­va­tion and In­vest­ment Sum­mit in Shang­hai on Oc­to­ber 23, 2018

Click on the im­age to see the full-sized ver­sion


And we’ve done all of this with­out rais­ing any VC cash.

End­points is built to with­stand the storms en­velop­ing dig­i­tal me­dia to­day thanks to the di­rect sup­port of our En­ter­prise and In­sid­er sub­scribers.  We’re hir­ing new jour­nal­ists, plan to dou­ble the au­di­ence, and have moved in­to a new head­quar­ters in Lawrence, Kansas that’ll serve as the nerve-cen­ter for End­points’ next stage of in­no­va­tion. New hires in mar­ket­ing, sales, and op­er­a­tions are in the works now to sup­port that. There’s a web­site re­vamp on tap. And there’s just so much more news we’d like to cov­er in trans­la­tion­al sci­ence and out­sourc­ing.

Most im­por­tant­ly: Our fi­nan­cial in­cen­tives are tied to pro­duc­ing a jour­nal­ism prod­uct that serves the core bio­phar­ma read­er.

Haven’t joined yet? Now is a great time and you can see one of the ben­e­fits above: a print (yes, print!) ver­sion of the 2018 class of new drug ap­provals. You’ll al­so get ac­cess to the lat­est edi­tion of bio­phar­ma’s top 100 VCs, and the en­tire pay­wall li­brary.

The most im­por­tant way you can di­rect­ly sup­port End­points is hav­ing your com­pa­ny sub­scribe to our $1,000/year flat-rate En­ter­prise plan (signup link). That’s an “un­lim­it­ed li­cense” for every em­ploy­ee un­der your cor­po­rate ban­ner. All of your col­leagues get ac­cess to pay­wall con­tent, reprint rights, PDF ex­port, and your HR team gets two pre­mi­um job post­ings at End­points Ca­reers. We have a VIP sup­port team who’ll work with you to get End­points set up for the rest of your team, too.

It’s a great val­ue, and you’re sup­port­ing the most im­por­tant part of our mod­el. The pric­ing is trans­par­ent and so is our re­new­al process.

For in­di­vid­u­als, we of­fer the In­sid­er plan at $200/year. Ex­tra ben­e­fits on top of the pay­wall ac­cess in­clude dis­count­ed rates to our ma­jor glob­al events line­up.

We’re al­so start­ing a se­ries of sub­scriber-on­ly net­work­ing mix­ers for In­sid­ers. The very first one will be in Durham, NC on Thurs­day Feb­ru­ary 21 at 6pm. I’ll be there along with our VP/Part­ner­ships Mike Peck. In­sid­ers will get an email next week with signup de­tails on this one and our fu­ture slate.

Grow­ing Plans

We’re go­ing through a ma­jor plat­form over­haul this year.

The look and feel of End­points hasn’t changed since we launched in June 2016. The orig­i­nal goal of our de­sign is to de­liv­er news with­out un­nec­es­sary or­na­ments, with a user ex­pe­ri­ence that feels fa­mil­iar no mat­ter what de­vice you’re on. But we’ve pub­lished over 5,000 news ar­ti­cles and near­ly 700 dai­ly re­ports now in the End­points style, and with that ex­pe­ri­ence we’ve iden­ti­fied a num­ber of ar­eas we can im­prove on. Some of it will be in­cre­men­tal like bet­ter search and im­prov­ing the archives. Oth­ers will be more vis­i­ble and feel like brand new fea­tures.

Ad­ver­tis­ing

Sub­scrip­tions are the lifeblood of this com­pa­ny. But in or­der to de­vel­op a sus­tained im­pact be­fit­ting a ma­jor news or­ga­ni­za­tion, ar­ti­cles must be able to trav­el far and wide, eas­i­ly dis­cov­er­able by new au­di­ences. Oth­er­wise, we run the risk of be­com­ing an in­sid­ers-on­ly re­port.

That is where ad­ver­tis­ing comes in. But noth­ing we do there is tra­di­tion­al.

I don’t be­lieve in squeez­ing web pages hard for lit­tle juice. That’s es­sen­tial­ly what many news pub­lish­ers do when you see pro­mot­ed links and ads that are at best ir­rel­e­vant and at worst have fol­lowed you around the In­ter­net to sell you some­thing you searched on ear­li­er. That kind of ap­proach cheap­ens the qual­i­ty of the con­tent sur­round­ing it, in my view. It has no place on a busi­ness news web­site.

Every ad unit you see on End­points is pur­chased in-house. These are high qual­i­ty im­pres­sions that are rel­e­vant to bio­phar­ma, brought to you by ad­ver­tis­ers that have been vet­ted. Our busi­ness team is led by Mike Peck, who comes to End­points af­ter serv­ing as a VP at Forbes and the New York Times. Mar­ket­ing pros can reach him at mike@end­pointsnews.com.

Busi­ness Mod­el

Sub­scrip­tions, events, ad­ver­tis­ing — in or­der of im­por­tance, that is the End­points busi­ness mod­el. Our mis­sion is to pro­duce the best dai­ly news re­port in bio­phar­ma, writ­ten for our core read­ers, but to make it as wide­ly avail­able as pos­si­ble so it has an im­pact and is dis­cov­er­able by new read­ers.

If you need End­points, we def­i­nite­ly need you. Again the best way to sup­port us is hav­ing your com­pa­ny sub­scribe to our $1,000/year flat-rate En­ter­prise plan (signup link). In­di­vid­u­als can signup for In­sid­er here.

To all of you who’ve joined — thank you. We’re build­ing some­thing to­geth­er.

ZS Per­spec­tive: 3 Pre­dic­tions on the Fu­ture of Cell & Gene Ther­a­pies

The field of cell and gene therapies (C&GTs) has seen a renaissance, with first generation commercial therapies such as Kymriah, Yescarta, and Luxturna laying the groundwork for an incoming wave of potentially transformative C&GTs that aim to address diverse disease areas. With this renaissance comes several potential opportunities, of which we discuss three predictions below.

Allogenic Natural Killer (NK) Cells have the potential to displace current Cell Therapies in oncology if proven durable.

Despite being early in development, Allogenic NKs are proving to be an attractive new treatment paradigm in oncology. The question of durability of response with allogenic therapies is still an unknown. Fate Therapeutics’ recent phase 1 data for FT516 showed relatively quicker relapses vs already approved autologous CAR-Ts. However, other manufacturers, like Allogene for their allogenic CAR-T therapy ALLO-501A, are exploring novel lymphodepletion approaches to improve persistence of allogenic cells. Nevertheless, allogenic NKs demonstrate a strong value proposition relative to their T cell counterparts due to comparable response rates (so far) combined with the added advantage of a significantly safer AE profile. Specifically, little to no risk of graft versus host disease (GvHD), cytotoxic release syndrome (CRS), and neurotoxicity (NT) have been seen so far with allogenic NK cells (Fig. 1). In addition, being able to harness an allogenic cell source gives way to operational advantages as “off-the-shelf” products provide improved turnaround time (TAT), scalability, and potentially reduced cost. NKs are currently in development for a variety of overlapping hematological indications with chimeric antigen receptor T cells (CAR-Ts) today, and the question remains to what extent they will disrupt the current cell therapy landscape. Click for more details.

Graphic: Kathy Wong for Endpoints News

What kind of biotech start­up wins a $3B syn­di­cate, woos a gallery of mar­quee sci­en­tists and re­cruits GSK's Hal Bar­ron as CEO in a stun­ner? Let Rick Klaus­ner ex­plain

It started with a question about a lifetime’s dream on a walk with tech investor Yuri Milner.

At the beginning of the great pandemic, former NCI chief and inveterate biotech entrepreneur Rick Klausner and the Facebook billionaire would traipse Los Altos Hills in Silicon Valley Saturday mornings and talk about ideas.

Milner’s question on one of those mornings on foot: “What do you want to do?”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Hal Barron, Endpoints UKBIO20 (Jeff Rumans)

'Al­tos was re­al­ly a once-in-a-life­time op­por­tu­ni­ty': Hal Bar­ron re­flects on his big move

By all accounts, Hal Barron had one of the best jobs in Big Pharma R&D. He made more than $11 million in 2020, once again reaping more than his boss, Emma Walmsley, who always championed him at every opportunity. And he oversaw a global R&D effort that struck a variety of big-dollar deals for oncology, neurodegeneration and more.

Sure, the critics never let up about what they saw as a rather uninspiring late-stage pipeline, where the rubber hits the road in the Big Pharma world’s hunt for the next big near-term blockbuster, but the in-house reviews were stellar. And Barron was firmly focused on bringing up the success rate in clinical trials, holding out for the big rewards of moving the dial from an average 10% success rate to 20%.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Executive Director of the EMA Emer Cooke (AP Photo/Geert Vanden Wijngaert)

Eu­ro­pean Par­lia­ment signs off on strength­en­ing drug reg­u­la­tor's abil­i­ty to tack­le short­ages

The European Parliament on Thursday endorsed a plan to increase the powers of the European Medicines Agency, which will be better equipped to monitor and mitigate shortages of drugs and medical devices.

By a vote of 655 to 31, parliament signed off on a provisional agreement reached with the European Council from last October, in which the EMA will create two shortage steering groups (one for drugs, the other for devices), a new European Shortages Monitoring Platform to facilitate data collection and increase transparency, and on funding for the work of the steering groups, task force, working parties and expert panels that are to be established.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,300+ biopharma pros reading Endpoints daily — and it's free.

FDA+ roundup: FDA's neu­ro­science deputy de­parts amid on­go­ing Aduhelm in­ves­ti­ga­tions; Califf on the ropes?

Amid increased scrutiny into the close ties between FDA and Biogen prior to the controversial accelerated approval of Aduhelm, the deputy director of the FDA’s office of neuroscience has called it quits after more than two decades at the agency.

Eric Bastings will now take over as VP of development strategy at Ionis Pharmaceuticals, the company said Wednesday, where he will provide senior clinical and regulatory leadership in support of Ionis’ pipeline.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Sec­ondary patents prove to be key in biosim­i­lar block­ing strate­gies, re­searchers find

While the US biosimilars industry has generally been a disappointment since its inception, with FDA approving 33 biosimilars since 2015, just a fraction of those have immediately followed their approvals with launches. And more than a handful of biosimilars for two of the biggest blockbusters of all time — AbbVie’s Humira and Amgen’s Enbrel — remain approved by FDA but still have not launched because of legal settlements.

Hal Barron (GSK via YouTube)

GSK R&D chief Hal Bar­ron jumps ship to run a $3B biotech start­up, Tony Wood tapped to re­place him

In a stunning switch, GlaxoSmithKline put out word early Wednesday that R&D chief Hal Barron is exiting the company after 4 years — a relatively brief run for the man chosen by CEO Emma Walmsley in late 2017 to turn around the slow-footed pharma giant.

Barron is being replaced by Tony Wood, a close associate of Barron’s who’s taking one of the top jobs in Big Pharma R&D. He’ll be closer to home, though, for GSK. Barron has been running a UK and Philadelphia-based research organization from his perch in San Francisco.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,300+ biopharma pros reading Endpoints daily — and it's free.

Troy Wilson, Kura CEO

FDA lifts par­tial hold on Ku­ra's Phase Ib AML pro­gram as biotech re­dou­bles mit­i­ga­tion ef­forts

Kura Oncology is clear to resume studies for its early-stage leukemia program after the FDA lifted a clinical hold Thursday afternoon.

Regulators had placed the hold on a Phase Ib study of KO-539, an experimental oral treatment for some genetic subsets of acute myeloid leukemia last November after a patient died while taking the drug. Kura expects to begin enrolling patients again imminently, CEO Troy Wilson told Endpoints News.

A Sen­ate bill wants to even an 'un­lev­el play­ing field' for do­mes­tic, for­eign in­spec­tion drop-ins amid back­log

Amid geopolitical tensions between the US and China, two Republican senators are calling for a bill that would aim to strike a balance on domestic and foreign inspection requirements from the FDA.

Sens. Mike Braun (R-IN) and Joni Ernst (R-IA) have penned a bill called the Creating Efficiency in Foreign Inspections Act. It contains a bit of rhetoric, highlighting “communist China” not once, but twice in the release, but states that the goal is to even the playing field between foreign and American manufacturers.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,300+ biopharma pros reading Endpoints daily — and it's free.